Education
About Us
Working with TipRanks
Follow Us
Hls Therapeutics (TSE:HLS)
:HLS
Total Valuation
HLS Therapeutics Inc has a market cap or net worth of C$127.81M. The enterprise value is C$188.55M.
Market CapC$127.81M
Enterprise ValueC$188.55M
Share Statistics
HLS Therapeutics Inc has 31.79M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding31.79M
Owened by Insiders0.51%
Owened by Instutions1.57%
Financial Efficiency
HLS Therapeutics Inc’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-27.55%
Return on Assets (ROA)-12.29%
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00%
Revenue Per EmployeeC$615,423.913
Profits Per Employee-C$213,641.304
Employee Count92
Asset Turnover0.35
Inventory Turnover0.99
Valuation Ratios
The current PE Ratio of HLS Therapeutics Inc is 0.00. HLS Therapeutics Inc’s PEG ratio is 0.00.
PE Ratio0.00
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.00
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.00
Income Statement
In the last 12 months, HLS Therapeutics Inc had revenue of C$56.62M and earned -C$19.66M in profits. Earnings per share was -C$0.62.
RevenueC$56.62M
Gross ProfitC$47.62M
Operating Income-C$8.23M
Pretax Income-C$15.58M
Net Income-C$19.66M
EBITDA14.13M
Earnings Per Share (EPS)-0.62
Cash Flow
In the last 12 months, operating cash flow was C$8.00M and capital expenditures -C$15.00K, giving a free cash flow of C$7.99M billion.
Operating Cash FlowC$8.00M
Free Cash FlowC$7.99M
Free Cash Flow per ShareC$0.25
Dividends & Yields
HLS Therapeutics Inc pays an annual dividend of C$0.05, resulting in a dividend yield of
Dividend Per ShareC$0.05
Dividend Yield
Payout Ratio
Free Cash Flow Yield0.00%
Earnings Yield―
Stock Price Statistics
Beta0.50
52-Week Price Change-22.05%
50-Day Moving Average4.24
200-Day Moving Average3.70
Relative Strength Index (RSI)67.28
Average Volume (3m)9.48K
Important Dates
HLS Therapeutics Inc upcoming earnings date is May 8, 2025, Before Open.
Last Earnings DateMar 13, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend DateApr 27, 2023
Financial Position
HLS Therapeutics Inc as a current ratio of 1.57, with Debt / Equity ratio of 0.93
Current Ratio1.57
Quick Ratio1.17
Debt to Market Cap0.00
Net Debt to EBITDA2.85
Interest Coverage Ratio0.00
Taxes
In the past 12 months, HLS Therapeutics Inc has paid C$4.07M in taxes.
Income TaxC$4.07M
Effective Tax Rate-26.14%
Enterprise Valuation
HLS Therapeutics Inc EV to EBITDA ratio is 2.85, with an EV/FCF ratio of 6.13.
EV to Sales0.87
EV to EBITDA2.85
EV to Free Cash Flow6.13
EV to Operating Cash Flow6.12
Balance Sheet
HLS Therapeutics Inc has C$17.46M in cash and marketable securities with C$66.45M in debt, giving a net cash position of C$48.99M billion.
Cash & Marketable SecuritiesC$17.46M
Total DebtC$66.45M
Net CashC$48.99M
Net Cash Per ShareC$1.54
Tangible Book Value Per ShareC$0.00
Margins
Gross margin is 84.11%, with operating margin of 0.00%, and net profit margin of -34.71%.
Gross Margin84.11%
Operating Margin0.00%
Pretax Margin-27.52%
Net Profit Margin-34.71%
EBITDA Margin30.41%
EBIT Margin-9.71%
Analyst Forecast
The average price target for HLS Therapeutics Inc is C$5.92, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetC$5.92
Price Target Upside44.04%
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-8.80%
EPS Growth Forecast26.77%